Neostigmine/glycopyrronium bromide

Neostigmine/glycopyrronium bromide
Combination of
Neostigmine	Cholinesterase inhibitor
Glycopyrronium bromide	Antimuscarinic agent
Clinical data
Trade names	Prevduo
Other names	Neostigmine methylsulfate/glycopyrrolate, glycopyrronium bromide/neostigmine metilsulfate
License data	US DailyMed: Neostigmine methylsulfate and glycopyrrolate;
Routes of; administration	Intravenous
ATC code	N07AA51 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only)[1]; US: ℞-only[2];

Neostigmine/glycopyrronium bromide, sold under the brand name Prevduo , is a fixed-dose combination medication used for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[2] It contains neostigmine as the methylsulfate, a cholinesterase inhibitor, and glycopyrronium bromide, an antimuscarinic agent.[2]

Neostigmine/glycopyrronium bromide was approved for medical use in the United Kingdom in 2007,[1] and in the United States in February 2023.[3]

Medical uses

Neostigmine/glycopyrronium bromide is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following non-depolarizing neuromuscular blocking agent reversal administration.[3]

References

"Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.
"Archived copy" (PDF). Archived (PDF) from the original on 26 February 2023. Retrieved 25 February 2023.{{cite web}}: CS1 maint: archived copy as title (link)
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216903Orig1s000ltr.pdf Archived 26 February 2023 at the Wayback Machine This article incorporates text from this source, which is in the public domain.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Glycopyrronium_Bromide_and_Neostigmine_Metilsulfate_SmPC-1] "Glycopyrronium Bromide and Neostigmine Metilsulfate 0.5mg/2.5mg per ml Solution for Injection - Summary of Product Characteristics (SmPC)". (emc). 12 November 2018. Archived from the original on 7 August 2022. Retrieved 25 February 2023.

[Prevduo_FDA_label-2] "Archived copy" (PDF). Archived (PDF) from the original on 26 February 2023. Retrieved 25 February 2023.{{cite web}}: CS1 maint: archived copy as title (link)

[Prevduo_approval_letter-3] ttps://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216903Orig1s000ltr.pdf Archived 26 February 2023 at the Wayback Machine This article incorporates text from this source, which is in the public domain.